Synthesis towards several potential inhibitors of Anthrax Lethal Factor through organoboron chemistry
Document Type
Oral Presentation
Campus where you would like to present
SURC Ballroom C/D
Start Date
16-5-2013
End Date
16-5-2013
Abstract
Anthrax is an acute disease caused by infection of active spores from the bacteria Bacillus anthracis. Immediate treatment is required for individuals infected with the bacteria, resulting in a relatively small window of opportunity to prevent death. Bacillus anthracis secretes a toxin composed of three proteins: lethal factor (LF), edema factor (EM), and protective antigen (PA). Current treatments for infection are limited to a window of opportunity which merits a need for new immediate acting inhibitors. This research has developed three novel potential Anthrax LF inhibitors including analogs to be synthesized. Currently, one of the three initial compound pathways has been completed with improvements to the synthetic route during production. The proposed target compounds could potentially serve as a more effective treatment to acute infection caused by Bacillus anthracis.
Recommended Citation
Frank, Michael, "Synthesis towards several potential inhibitors of Anthrax Lethal Factor through organoboron chemistry" (2013). Symposium Of University Research and Creative Expression (SOURCE). 120.
https://digitalcommons.cwu.edu/source/2013/posters/120
Poster Number
47
Additional Mentoring Department
Chemistry
Synthesis towards several potential inhibitors of Anthrax Lethal Factor through organoboron chemistry
SURC Ballroom C/D
Anthrax is an acute disease caused by infection of active spores from the bacteria Bacillus anthracis. Immediate treatment is required for individuals infected with the bacteria, resulting in a relatively small window of opportunity to prevent death. Bacillus anthracis secretes a toxin composed of three proteins: lethal factor (LF), edema factor (EM), and protective antigen (PA). Current treatments for infection are limited to a window of opportunity which merits a need for new immediate acting inhibitors. This research has developed three novel potential Anthrax LF inhibitors including analogs to be synthesized. Currently, one of the three initial compound pathways has been completed with improvements to the synthetic route during production. The proposed target compounds could potentially serve as a more effective treatment to acute infection caused by Bacillus anthracis.
Faculty Mentor(s)
Levente Fabry-Asztalos